DOCSLIB.ORG

Supplemental Complement Component C9 Enhances the Capacity of Neonatal Serum to Kill Multiple Isolates of Pathogenic Escherichia Coli'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Complement Component C9 Enhances the Capacity of Neonatal Serum to Kill Multiple Isolates of Pathogenic Escherichia Coli' 0031-3998/94/3504-0389$03.00/0 PEDIATRIC RESEARCH Vol. 35, No.4, 1994 Copyright © 1994 International Pediatric Research Foundation. Inc. Printed in U.S.A. Supplemental Complement Component C9 Enhances the Capacity of Neonatal Serum to Kill Multiple Isolates of Pathogenic Escherichia coli' HERBERT A. LASSITER, JESSICA L. WILSON, RICHARD C. FELDHOFF, JOHN M. HOFFPAUIR, AND KATHLEEN M. KLUEBER Division of Neonatology. Department ofPediatrics {H.AL. JL W.{. the Department ofAnatomical Sciences and Neurobiology {J.M.H.. K.M.K.]. and the Department of Biochemistry {R.C.F.]. University ofLouisville School of Medicine. Louisv ille. Kentucky 40292 ABSTRACf. Previous studies demonstrated that, com­ BPBS·, PBS with 1 mM MgCh and 0.5% BSA pared with adult serum, neonatal serum contained a dimin­ BPBS··, PBS with 1 mM MgCh, 0.5% BSA, and 0.15 ished concentration of complement component C9 and that mMCaCh supplemental C9 enhanced the capacity of neonatal serum to kill an isolate of Escherichia coli. Therefore, experi­ ments were designed to determine the mechanisms by which supplemental C9 enhances the bactericidal capacity of neonatal serum and to determine whether supplemental Escherichia coli is the second most common bacterium iso­ C9 enhances the capacity of neonatal serum to kill several lated from the blood of septic neonates (I, 2). Newborn infants different pathogenic strains of E. coli.A radiobinding assay acquire E. colisepsis for reasons that are not completely under­ and immunogold electron microscopy using a monoclonal stood. In the adult host, complement-mediated cytolysis (bac­ anti-C9 antibody revealed that, compared with 40% adult teriolysis) has been proposed as a mechanism of defense against serum, neonatal serum deposited a diminished quantity of invasion by gram-negative bacteria (3-5). However, compared C9 onto E. coli 07w:Kl:NM. Supplemental C9 (75 mgfL) with serum from adults, serum from human neonates kills E. significantly enhanced the quantity of C9 deposited by the coli inefficiently (6, 7) , The ninth component of complement neonatal serum. Treatment with 10 mM MgEGTA (a (C9) is a circulating glycoprotein that is required for efficient mixture of 100 mM MgCh and 100 mM EGTA that blocks complement-mediated cytolysis of E. coli(8-10). The concentra­ activation of the classic complement pathway but leaves tion of C9 is diminished in the sera of human neonates (II, 12). the alternative pathway intact) abolished the capacity of Moreover, supplemental C9 enhanced the capacity of sera from neonatal serum to deposit C9 and to kill the bacteria. newborn infants to kill a pathogenic isolate of E. coli(12). Supplemental C9 enhanced the capacity of neonatal serum The mechanism by which supplemental C9 increases the bac­ to kill eight different blood isolates of E. coli. Therefore, tericidal capacity of neonatal serum is not known. Also, whether supplemental C9 enhanced the capacity of neonatal serum supplemental C9 affects the bactericidal activity of neonatal to kill E. coli by increasing the total quantity of C9 depos­ serum against other isolates of E. coli is not known. Therefore, ited via activation of the classic complement pathway. experiments were designed to determine the effect of supple­ Neonatal serum contained sufficient quantities of classic mental C9 on the kinetics of bacterial killing by neonatal serum, pathway components, other than C9, to deposit the supple­ the deposition of C9 onto the surface of E. coli, and the capacity mental C9 onto E. coli and to enhance bacterial killing. of neonatal serum to kill several different isolates of pathogenic The bactericidal activity of neonatal serum against multiple E. coli. isolates of pathogenic E. coli was increased after C9 sup­ plementation. We speculate that C9 deficiency may beone MATERIALS AND METHODS of the defects in antibacterial host defense that predisposes neonates to the acquisition of E. coli sepsis. (Pediatr Res Buffers and reagents. The following buffers and reagents were 35:389-396,1994) used: Dulbecco PBS (Media Tech, Washington, DC), pH 7.4; BPBS+; BPBS++; 100mM MgEGTA (Sigma, St. Louis, MO), pH 7.4; and tryptic soy broth (Difco Laboratories, Detroit, MI). Abbreviations Buffers used in the radiobinding assays and the immunogold MgEGTA, 100 mM MgCh and 100 mM EGTA assays contained 0.02% sodium azide (Sigma). Buffers used in minimum concentration of adult serum required to the bactericidal assays contained no bacteriostatic agents. kill 90% of an isolate of Escherichia coli during 90 min Bacteria. Eight isolates of E. coliwere obtained from the blood of incubation of eight septic neonates who were patients at the Neonatal Intensive Care Unit of Kosair Children's Hospital, Louisville, Received June I. 1993: accepted November 19. 1993. KY. The serotype of each organism was determined at the E. Correspondence and reprint requests : Herbert A. Lassiter. M.D.•Division of Neonatology. Department of Pediatrics. Un iversity of Louisville School of Medi­ coli Reference Center of Pennsylvania State University, Univer­ cine, Louisville. KY 40292. sity Park, PA (Table I). The bacteria were grown overnight and Supported by grants from the Division of Neonatology. Department of Pediat­ stored in 5-mL aliquots of tryptic soy broth at - 70"C. Before an rics, University of Louisville School of Medicine. and the Alliant Community Trust experiment, 35 mL of fresh broth were added, and the bacteria Fund. Louisville. Kentucky. were incubated at 37"C for 3 to 4 h to bring the organisms to log I Presented in part at the 61st annual meeting of the Society for Pediatric Research, Baltimore , MD, May 1992 and at the 62nd annual meeting of the Society phase. The bacteria were then washed three times in BPBS" or for Pediatric Research , Washington, DC. May 1993. BPBS+ and adjusted by absorbance at 600 nm to a concentration 389 390 LASSITER ET AL. Table I. Characteristics ofE. coli isolates" 5.,-----------------------, Isolate LC (%) Serotype 90 I 20 07w:KI:NM ll.i 4 2 30 O(-):H(-) "0 3 40 07w:K I:8w 0­ M 4 60 O(-):KI:H(-) III 5 30 OI :KI:NM ,.: 6 30 O(-):KI:NM 7 40 O{-):H(-) en 2 8 50 07:KI:NM o E * Each isolate was obtained from the blood of a septic neonate. ep 1 Cl Not 140 C Delacled • NEONATAL SERUII AdS AdS NooS NooSCg NooSCg II NEONATAL SERUII • ct 120 + + § • ADULT SERUII MgEGTA MgEGTA 100 I&i Fig. 3. Effect of supplemental C9 on the deposition of C9 onto E. -' 0( 80 coliby neonatal serum. E. coli07w:KI:NM were incubated with pooled adult serum (AdS), AdS treated with MgEGTA, pooled neonatal serum a: :;:) 10 (NeoS), NeoS supplemented with C9 (NeoSC9), and C9-supplemented en NeoS treated with MgEGTA . As determined by radiobinding assay, the 40 results are depicted as the mean (+ SE) Quantity of 12' 1-labeled anti-C9 antibodies specifically bound to the bacteria (n = 3). *, p < 0.0 I vsadult 20 serum ; .., p < 0.01 vs pooled neonatal serum. C9 deposition onto E. coli, mediated by the classic complement pathway, was inefficient in the 15 30 45 10 75 10 pooled neonatal serum but was enhanced by supplemental C9. TIME (MINUTES) The serum from each neonate contained lessthan 0.1 g/L of IgA Fig. I. Effect of supplemental C9 on the bactericidal activity of and less than 0.2 gjL of IgM, as determined by single radial neonatal serum. E. coli 07w:KI:NM were incubated in pooled neonatal immunodiffusion (Endplate IgA and Endplate IgM, Kallestad, serum (diamonds), pooled neonatal serum supplemented with C9 Austin, TX) (13). Most experiments used serum that was pooled (squares), and pooled adult serum (circles). As determined by bactericidal from the blood of the 20 neonates. Sera were also obtained and assay, the values are depicted as the mean bacterial survival ± SE. *, p < pooled from five healthy adult volunteers. The serum was sepa­ 0.05 vs adult serum and p < 0.05 vs C9-supplemented neonatal serum. rated from the clotted blood by centrifugation and passed The onset of bacterial killing was delayed in neonatal serum compared through a filter to ensure the removal of bacterial con­ with adult serum. However, in neonatal serum, supplemental C9 accel­ taminants. Individual sera and the pooled serum were stored at erated the onset of bacterial killing. - 70·C in sterile vials. Complement component C9. Purified C9 (Lot no. A40TT2390 I) was purchased from Quidel Corporation (San I Diego, CA) as a solution containing 1000 of C9jmL of PBS without bacteriostatic agents. This C9 preparation was isolated I&i 5 by the method of Biesecker and Muller-Eberhard (14) and was ·0 0- subjected by the manufacturer to an antiimpurities solid-phase M 4 1ft immunoaffinity column containing the IgG fraction isolated ,.: from monospecific goat antihuman C3, -C5, -C6, -C7, and -C8 i 3 to insure the complete removal of these complement proteins. fj 2 SDS-PAGE and hemolytic assays by the manufacturer demon­ strated that more than 95% of the protein in the solution was • 1 pure C9 and that the solution was completely free ofC3, C5, C6, ( C7, and C8 functional activities. ell To confirm the purity of the C9 preparation used in these C 10 studies, various assayswere also performed in our laboratory. By Fig. 2. Deposition of C9 onto E. coli by neonatal sera. E. coli nephelometry (Beckman Array Protein System, Beckman Instru­ 07w:KI:NM were incubated with pooled adult serum (AdS) and with ments, Brea, CA), the solution did not contain detectable IgA, sera from 10 healthy neonates (numbers 1-10). As determined by ra­ IgM, or IgG. Because neonatal serum normally contains dimin­ diobinding assay, the results are depicted as the mean (+ SE) Quantity of ished concentrations of various complement components, such '2sl_labeledanti-C9 ant ibodies specifically bound to the bacteria (n = 4).
Load more

Recommended publications
  • Test Directory
    800.541.7891 509.755.8600 Test Directory Fax 509.921.7107 Billing Code Test Code [sunquest] (1,3)-BETA-D-GLUCAN (FUNGITELL) 13BGA 13BGA Synonyms Fungitell; Glucan Container Type Red top tube (plain) Store and Transport Refrigerated Specimen Type Serum Preferred Volume 2 mL Minimum Volume 0.5 mL Specimen Processing Separate serum from cells within 2 hours of collection and transfer to a standard PAML aliquot tube Room Temp Unacceptable Refrigerated 2 weeks Frozen (-20°C) 2 weeks Unacceptable Condition Hemolyzed, lipemic and icteric samples Reference Laboratory ARUP Reference Lab Test Code 2002434 CPT Codes 87449 Test Schedule Mon-Fri Turnaround Time 2-4 days Method Semi-Quantitative Colorimetry Test Includes (1,3-beta-D-glucan, pg/mL; (1,3-beta D-glucan Interpretation. Notes Reference ranges for pediatric patients (less than 18 years old) have not been established. Assay ranges were validated in adult subjects. Supply Item Number 1372 Billing Code Test Code [sunquest] 1, 5 ANHYDROGLUCITOL (GLYCOMARK) GLYMAR GLYMAR Synonyms Anhydroglucitol, 1,5 AD; GlycoMark® Container Type Serum separator tube (gold, brick, SST, or corvac) Store and Transport Refrigerated Specimen Type Serum Preferred Volume 1 mL Minimum Volume 0.2 mL Specimen Processing Allow serum specimen to clot completely at room temperature. Separate serum or plasma from cells and transfer to a standard PAML aliquot tube Room Temp 1 week Refrigerated 1 week Frozen (-20°C) 1 month Alternate Specimens Lavender (EDTA) Reference Laboratory ARUP Reference Lab Test Code 0081335 CPT Codes 84378 Test Schedule Mon-Fri Turnaround Time 2-4 days Method Quantitative Enzymatic Test Includes GlycoMark, ug/mL.
    [Show full text]
  • Anti-Insulin Antibodies in Von Freien Und Totalen Anti-Insulin Dans Le Sérum Humain Human Serum Antikörpern in Humanserum
    Février 2019 – Modèle 014 Cisbio Bioassays Parc Marcel Boiteux – BP 84175 – 30200 Codolet / France - Tél. 33 (0)4.66.79.67.00 ANTI-INSULIN AAI ANTIBODIES Trousse pour le dosage radioimmunologique Kit for radioimmunoassay for determination Kit zur radioimmunologischen Bestimmung des anticorps anti-insuline libres et totaux of free and total anti-insulin antibodies in von freien und totalen Anti-Insulin dans le sérum humain human serum Antikörpern in Humanserum La trousse contient : Kit content : Inhalt des Kits : Traceur ≤ 52 kBq 2 x 5 mL Tracer ≤ 52 kBq 2 x 5 mL Tracer ≤ 52 kBq 2 x 5 mL Solution précipitante 1 x 100 mL Precipitating solution 1 x 100 mL Präzipitationslösung 1 x 100 mL Réactif d’extraction 1 x 10 mL Extraction reagent 1 x 10 mL Extraktionsreagenz 1 x 10 mL Tampon de neutralisation 1 x 10 mL Neutralization buffer 1 x 10 mL Neutralisationspuffer 1 x 10 mL Contrôle négatif (C1) 1 x qsp 1 mL Negative control 1 x qs 1 mL Negativkontrolle 1 x qs 1 mL Contrôle positif (C2) 1 x qsp 1 mL Positive control 1 x qs 1 mL Positivkontrolle 1 x qs 1 mL Mode d’emploi 1 Instruction for use 1 Gebrauchsinformation 1 Attention : Certains réactifs contiennent de l’azoture de sodium Warning : Some reagents contain sodium azide Achtung : Einige Reagenzien enthalten Natriumazid Kit per il dosaggio radioimmunologico degli Equipo radioinmunológica para la Δοκιμασία για τον ραδιοανοσολογικό anticorpi anti-insulina liberi e totali nel siero determinación de los anticuerpos anti- προσδιορισμό των ελεύθερων και συνολικών umano insulina libres y totales en suero humano αντισωμάτων έναντι της ινσουλίνης στον ανθρώπινο ορό .
    [Show full text]
  • BLOOD TYPE) Methodology: Tube Agglutination BBK Set Up: Daily, As Ordered ABORH BLOOD TYPE 6.0 Ml Whole Blood (Pink) ABORH Report Available: Same Day
    LAB OE TEST REFERENCE SPECIMEN ORDER ORDER PROCEDURE RANGE REQUIREMENTS MNEMONIC NAME ABORH GROUP (BLOOD TYPE) Methodology: Tube agglutination BBK Set up: Daily, as ordered ABORH BLOOD TYPE 6.0 mL whole blood (Pink) ABORH Report available: Same day CPT Code: 86900, 86901 ACA or ACLA - See Anti-Cardiolipin Antibodies ACE - see Angiotensin-1 Converting Enzyme ACETAMINOPHEN, SERUM Methodology: Immunoassay 1 mL blood (Gn -Li (PST)) Set up: Daily, as ordered or LAB ACETAMINOPHEN Accompanies report Report available: Same day 1 mL serum (SS) ACET Minimum: 0.5 mL CPT Code: 80329 ACETYLCHOLINE RECEPTOR 1.0 mL serum (SS) BINDING ANTIBODIES (QUEST 206) Minimum: 0.5 mL ACETYLCHOLINE BINDING Methodology: RIA LAB Accompanies report RECEP Set up: Tues-Sat Allow serum to clot at room ACETYL BIND Report available: 1-2 days temperature. Serum should be separated from cells within 1 CPT Code: 83519 hour of collection. ACETYLCHOLINE RECEPTOR BLOCKING ANTIBODIES (QUEST 34459) 1.0 mL serum (SS) centrifuge ACETYLCHOLINE Methodology: RIA with 1 hr of collection LAB Accompanies report BLOCKING RECEP Set up:Mon, Wed, Fri ACETYL BLO Report available: Next day Minimum:0.5 mL CPT Code: 83519 ACETYLCHOLINE RECEPTORMODULATING ANTIBODY (QUEST 26474) 1 mL serum (SS) ACETYLCHOL LAB Methodology: RIA Accompanies report MODULATING RECEP ACETYL MOD Set up: Tue,Thur,Sun Minimum: 0.5 mL Report available: 5 days CPT Code: 83519 ACETYLCHOLINESTERASE, QUALITATIVE, GEL ELECTROPHORESIS (QUEST 185314) This test is automatically performed on all 1.5 mL Amniotic fluid, ROOM Alpha-Fetroprotein
    [Show full text]
  • KPNW Specimen Requirements ***Please Hit 'Ctrl'+'F' to Open the 'Find on This Page' Funtion
    Page 1 of 368 KPNW Specimen Requirements ***Please hit 'Ctrl'+'F' to open the 'Find on this page' funtion. Panel Name Panel Description Preferred Collection/Volume: RED 10 No Gel Barrier Tubes Volume: 1.0 mL Serum Alternative Collection: GRN Li Hep or LAV EDTA Volume: 1.0 mL Plasma TAT: Report available: 5 Days Test Schedule: Saturday Morning Method: Liquid Chromatography/Tandem Mass Spectrometry Test Facility: Quest Diagnostics Nichols Inst San Juan Capistrano 33608 Ortega Highway San Juan Capistrano, CA 92690-6130 Clinical Data: 11-Deoxycortisol (Compound S) is useful in diagnosing patients with 11-beta- hydroxylase deficiency (second leading cause of congenital adrenal hyperplasia) and 11-Deoxycortisol primary (adrenal failure) or secondary (hypothalmic-pituitary ACTH deficiency) adrenal insufficiency. Patient Preparation: An early morning specimen is preferred Specimen Stability: Room Temperature: 4 days Refrigerated: 4 days Frozen: 4 weeks Ship serum frozen or refrigerated Test Code: CHANTILLY T.C.30543 TO SJC TC 30543X Processing: Centrifuge and aliquot into Referred Tests aliquot tube. Note if serum or plasma on specimen. Freeze solid. Transport: Transport frozen on ice. Preferred Collection/Volume: Preserve 24-hour urine with 25 mL of 50% Acetic Acid (preferred) or 30 mL 6N HCl or 1 gram Boric Acid/100 mL (acceptable) during collection. Refrigerate during collection. TAT: Next Day Test Schedule: Monday-Friday Night Method: Colorimetric Test Facility: Quest Diagnostics Nichols Institute 14225 Newbrook Drive Chantilly, VA 20153 17 Ketosteroids Total Pediatric 24 Hr Urine Labeling: Please specify on the request form and on the urine container the patient's age, sex, and (Includes Creatinine the total 24-hour urine volume Ratio) Specimen Stability: Room Temperature: 8 hours Refrigerated: 7 days Frozen: 30 days (-20c) Please specify on the request form and on the urine container the patient's age, sex, and the total 24-hour urine volume.
    [Show full text]
  • 1 Detection of Antibodies Directed to the N-Terminal Region of GAD Is
    Page 1 of 30 Diabetes Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes Short running title: Improved specificity of autoantibodies to N-terminally truncated GAD Alistair JK Williams1, Vito Lampasona2, Michael Schlosser3, Patricia W Mueller4, David L Pittman5, William E Winter5, Beena Akolkar6, Rebecca Wyatt1, Cristina Brigatti2, Stephanie Krause7, Peter Achenbach7 and Participating Laboratories 1. School of Clinical Sciences, University of Bristol, Bristol, UK 2. Division of Genetics and Cell Biology & Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy 3. Department of Medical Biochemistry and Molecular Biology and Institute of Pathophysiology, University Medical Center of Greifswald, Karlsburg, Germany 4. Molecular Risk Assessment Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, USA 5. Department of Pathology, University of Florida, Gainesville, FL, USA 6. Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA 7. Institute of Diabetes Research, Helmholtz Zentrum München, and Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Neuherberg, Germany Correspondence to – Alistair Williams Diabetes and Metabolism, School of Clinical Sciences Learning and Research Building, Southmead Hospital Bristol BS10 5NB Fax: +44 117 323 5336 Tel: +44 117 414 7900 [email protected] Word count: 2836 Figures: 4 Supplemental figures: 3 Supplemental table: 1 Supplemental appendix: 1 1 Diabetes Publish Ahead of Print, published online May 13, 2015 Diabetes Page 2 of 30 ABSTRACT Autoantibodies to glutamate decarboxylase (GADA) are sensitive markers of islet autoimmunity and type 1 diabetes.
    [Show full text]
  • Technology Development in the Field of Ligand Binding Assays Comparison Between ELISA and Other Methods
    20-X5 Technology Development inthe Field of Ligand Binding Assays Comparison between ELISA and other methods Tanya Al-Khafaf, Björn Ancker Persson, Johanna Cederblad, Albert Häggström, Reneh Kostines, Lina Löfström, Ella Schleimann-Jensen Client: Mercodia AB Client representative: Henning Henschel Supervisor: Lena Henriksson 1MB332, Independent Project in Molecular Biotechnology, 15 hp, spring semester 2020 Master Programme in Molecular Biotechnology Engineering Biology Education Centre, Uppsala University Abstract In this project, given to us by Mercodia AB, research in the field of im- munoassays is done in order to investigate if there are methods that are better than the conventional ELISA. ELISA is known to have some issues, such as ”The Hook effect”, many washing steps and cross-reactivity with the antibod- ies used in the assay. Therefore the need of other methods has arised. The result of the research showed that there are a huge number of methods that measure specific biomarkers. In this report 17 different techniques are presented. These techniques are: Mass Spectrometry (MS), Chemilumines- cence Immunoassay (CLIA), AlphaLISA, Lateral Flow Immunoassay (LFIA), Microfluidics-based Immunoassays, Paper Based Immunoassays, Biosensors and Aptasensors, Immuno-PCR, Proximity Ligand Assay (PLA), Proximity Extension Assays (PEA), Meso-scale discovery (MSD), Multiplex Assay, Dig- ital Bioassay, Bioluminescence Resonance Emission Transfer (BRET), Homo- geneous Time Resolved Fluorescence (HTRF) and NanoBiT. Each of the listed methods are compared according to several parameters such as specificity, sen- sitivity, measure range, sample volume, degree of automation, runtime and cost for each analyzed sample. The methods that showed an upward trend were: AlphaLISA, BRET, Biosen- sors, CLIA, Digital ELISA, methods using gold nanoparticles (AuNPs), HTRF, Immuno-PCR, Lateral Flow, MSD, Microfluidics, Multiplex methods, NanoBiT, paper-based, PEA, Simoa and Single molecule detection.
    [Show full text]
  • Role of Complement in Mouse Macrophage Binding of Haemophilus Influenzae Type B
    Role of complement in mouse macrophage binding of Haemophilus influenzae type b. G J Noel, … , D M Mosser, P J Edelson J Clin Invest. 1990;85(1):208-218. https://doi.org/10.1172/JCI114414. Research Article Previous in vivo studies demonstrated that clearance of encapsulated Haemophilus influenzae from blood is associated with the deposition of C3 on these bacteria and is independent of the later complement components (C5-C9). Since clearance of encapsulated bacteria is determined by phagocytosis of bacteria by fixed tissue macrophages, we studied the interaction of H. influenzae type b with macrophages in vitro. Organisms bound to macrophages in the presence of nonimmune serum. Binding was not evident in heat-treated serum or in serum from complement depleted animals and was inhibited by F(ab')2 fragments of antibody to C3 and by blockade of the macrophage complement receptor type 3. The majority of organisms bound in the presence of complement alone remained extracellular. Antibody in the form of convalescent serum or an IgG1 monoclonal to type b capsule did not increase the total number of organisms associated with macrophages, but did increase the number of organisms ingested. Furthermore, complement enhanced antibody- mediated ingestion. This in vitro study demonstrates that complement largely mediates binding of H. influenzae to macrophages. This binding may be critical in determining the early clearance of these bacteria from blood and may be an important mechanism of defense in the nonimmune, as well as the immune host. Find the latest version: https://jci.me/114414/pdf Role of Complement in Mouse Macrophage Binding of Haemophilus influenzae type b Gary J.
    [Show full text]
  • Test Code Test Name Components Specimen Method Comments
    Test Code Test Name Components Specimen Method Comments Report *CD3 *CD19 2 mL (1 mL min.) serum from 1 SST AND 6 mL (4 mL *CD16 + min.) whole blood in 2 Lavender Top (EDTA) tubes ABORTION CD56*TNF-alpha AND 3 mL (2 mL min.) whole blood in 1 Green Top Flow Cytometry, Sample by Mon 4 Z785 PANEL *HLA DR, DQA1 (Sodium Heparin) tube. Ship immediately at CLIA, PCR pm; Report Wed & DQB1 (Class II) 18–22°C. DO NOT REFRIGERATE OR FREEZE. Specify Typing time, date and clinical details on test request form. ABSOLUTE 3 mL (1 mL min.) whole blood in 1 Lavender Top Electrical H022 EOSINOPHIL Daily (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Impedance, VCS COUNT; AEC ABSOLUTE 3 mL (1 mL min.) whole blood in 1 Lavender Top Electrical H052 LYMPHOCYTE Daily (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Impedance, VCS COUNT ABSOLUTE 3 mL (1 mL min.) whole blood in 1 Lavender Top Electrical H051 NEUTROPHIL Daily (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Impedance, VCS COUNT ACETYLCHOLINE Sample by 7th of RECEPTOR 2 mL (0.5 mL min.) serum from 1 Red Top (No the month; RW002 (ACHR) Immunoassay Additive) tube. Ship refrigerated or frozen. Report after 2–3 BLOCKING weeks ANTIBODY This assay should not be requested for patients who have ACETYLCHOLINE recently received RECEPTOR 2 mL (1 mL min.) serum from 1 SST. Ship radio-isotopes Sample by Wed / S220 (ACHR) refrigerated or frozen. Avoid general anaesthetic or Radioimunoassay therapeutically or Sat 9 am; Report BINDING muscle relaxant drugs 24 hours prior to sampling.
    [Show full text]
  • Identification of Unique Antigenic Determinants in The
    Diabetes Care Volume 40, April 2017 561 fi Maria Acevedo-Calado,1 Eddie A. James,2 Identi cation of Unique Antigenic Michael P. Morran,3 Susan L. Pietropaolo,1 Qin Ouyang,1 David Arribas-Layton,2 Determinants in the Amino Marco Songini,4 Marco Liguori,4 Anna Casu,5 Richard J. Auchus,6 Terminus of IA-2 (ICA512) in Shuai Huang,7 Liping Yu,8 Aaron Michels,8 Roberto Gianani,1,9 and Childhood and Adult Autoimmune Massimo Pietropaolo1 Diabetes: New Biomarker Development Diabetes Care 2017;40:561–568 | DOI: 10.2337/dc16-1527 OBJECTIVE EMERGING TECHNOLOGIES AND THERAPEUTICS The characterization of diverse subtypes of diabetes is a dynamic field of clinical research and an active area of discussion. The objective of this study was to identify new antigenic determinants in the neuroendocrine autoantigen IA-2 (ICA512) and assess whether circulating autoantibodies directed to new IA-2 epitopes identify autoimmune diabetes in young and adult populations with diabetes. RESEARCH DESIGN AND METHODS 1Division of Diabetes, Endocrinology and Metab- Clinically diagnosed patients with type 2 diabetes (n = 258; diabetes duration: olism, Department of Medicine, Baylor College of 0.01–31 years) were evaluated using a new biomarker detecting autoantibodies Medicine, Houston, TX 2Benaroya Research Institute, University of directed to the extracellular domain of the neuroendocrine autoantigen IA-2 (IA- Washington, Seattle, WA 2ec). The proportion of IA-2ec autoantibodies was also evaluated in newly di- 3Department of Medicinal Chemistry, College of agnosed patients with type 1 diabetes (n = 150; diabetes duration: 0.04–0.49 Pharmacy, University of Toledo, Toledo, OH 4Diabetes Clinic, Department of Internal Medicine, years).
    [Show full text]
  • Manuscript Post Print
    Page 5 of 28 Analytical & Bioanalytical Chemistry 1 2 3 IMMUNOASSAY QUANTIFICATION OF HUMAN INSULIN ADDED TO 4 TERNARY PARENTERAL NUTRITION CONTAINERS: COMPARISON OF TWO 5 METHODS 6 7 Authors: Hélose Henry 1,2 , Damien Lannoy 1,2 , Nicolas Simon 1,2 , David Seguy 3, , Mich"le 8 5 1 1,2 1 1,2 9 D#Herbome% , Christine (arthélémy , (ertrand Décaudin , Thierry Dine , Pascal Odou 10 11 12 1. -niv. Lille, .A 7305 1 23ITA 1 2roupe de 3echerche sur les formes In7ectables et les Technologies 13 Associées, 8159000 Lille, 8rance 14 2. Pharmacy Institute, CH- Lille, 8159000 Lille, 8rance 15 3. -niversity of Lille, -995 ; LI3IC ; Lille Inflammation 3esearch International Center, 8159000 Lille, 8rance 16 . -niversity Hospital of Lille, Department of Nutrition, 8159000 Lille, 8rance 5. Immunoanalysis center, (iology and Pathology Center, CH- Lille, 8159000 Lille, 8rance 17 18 19 For Peer Review 20 21 22 Corresponding author: 23 24 Dr. Damien Lannoy 25 26 8aculté des Sciences Pharmaceutiques et (iologiques, .A 7305 ; 23ITA Laboratoire de 27 28 29 (iopharmacie, Pharmacie 2alénique et Hospitali"re, 3, rue du Professeur Laguesse ; (.P. 83, 30 31 59000 Lille Cedex, 8rance. 32 33 Tel: ?33 3 20 90 0 29 34 35 8ax: ?33 (0A3 20 95 90 09 36 37 38 .1mail address: damien.lannoyBuniv1lille2.fr. 39 40 41 42 43 44 AcCnowledgments: the authors especially want to thanC Mrs Alexandra Tavernier for her 45 46 extensive revision of the final manuscript. 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 Analytical & Bioanalytical Chemistry Page 6 of 28 1 2 3 ABSTRACT 4 5 Background : Adding insulin directly into infusion bags seems to be a useful method for 6 7 controlling hyperglycemia in patients under ternary parenteral nutrition (TPNA.
    [Show full text]
  • Insulin Autoantibodies As Determined by Competitive Radiobinding Assay Are Positively Correlated with Impaired Beta-Cell Function- the Ulm-Frankfurt Population Study
    Klinische Klin Wochenschr (1991) 69:736-741 Wochen- schrift 9Springer-Verlag 1991 Originals Insulin Autoantibodies as Determined by Competitive Radiobinding Assay are Positively Correlated with Impaired Beta-Cell Function- The Ulm-Frankfurt Population Study N. Yassin I, J. Seigler 1, M. Glfick 1, B.O. Boehm z, E. Heinze 3, E.F. Pfeiffer 1, and W.A. Scherbaum 1 1 Abteilung Innere Medizin I, Universit/it Ulm, Ulm 2 Abteilung Endokrinologie, Universit/it Frankfurt, Frankfurt 3 Kinderklinik, Universit/it Ulm, Ulm Summary. Out of a random population of 4208 of such patients [1, 2, 7, 17]. Therefore, their possi- non-diabetic pupils without a family history of ble role as predictive markers for the future devel- Type I diabetes 44 (1.05%) individuals had islet opment of Type I diabetes has attracted much at- cell antibody (ICA) levels greater or equal to 5 tention. Juvenile Diabetes Foundation (JDF) units. 39 of Islet cell antibodies (ICA) are associated with these ICA-positives could be repeatedly tested for newly diagnosed Type I diabetes and they have circulating insulin autoantibodies (CIAA) using a become indispensable tools for the initial screening competitive radiobinding assay. The results were to indicate the risk for the later development of compared with the insulin responses in the intrave- the disease. However, ICA may be transiently posi- nous glucose tolerance tests (IVGTT) and with tive and unrelated to diabetes [15], so that addi- HLA types. Six pupils were positive for CIAA. tional parameters should be evaluated. Recently All of them had complement-fixing ICA, and 5 autoantibodies against proinsulin were described of them were HLA-DR4 positive.
    [Show full text]
  • Systemic Lupus Erythematosus.Ann Rheum Dis 2010; 69: 1704-10
    The General Practice Guide to Autoimmune Diseases Edited by Y. Shoenfeld and P.L. Meroni The General Practice Guide to Autoimmune Diseases Edited by Y. Shoenfeld and P.L. Meroni PABST SCIENCE PUBLISHERS Lengerich, Berlin, Bremen, Miami, Riga, Viernheim, Wien, Zagreb Bibliographic information published by Deutsche Nationalbibliothek The Deutsche Nationalbibliothek lists this publication in the Deutsche Na- tionalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.ddb.de>. This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publi- cation does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulation and therefore free for general use. The authors and the publisher of this volume have taken care that the informa- tion and recommendations contained herein are accurate and compatible with the standards generally accepted at the time of publication. Nevertheless, it is difficult to ensure that all the information given is entirely accurate for all circumstances. The publisher disclaims any liability, loss, or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this volume. © 2012 Pabst Science Publishers, 49525 Lengerich http://www.pabst-publishers.de Printing: MercedesDruck, Berlin Typesetting: Hilmar Schlegel, Berlin Cover: Agentur für zeitgemäße Kommunikation Kaner Thompson www.kanerthompson.de ISBN 978-3-89967-770-6 The general practice guide to autoimmune diseases The development of autoimmunity and autoimmune diseases is believed to in- volve interactions“ between genes,hormones,and the environment and was labeled in 1989 as The mosaic of autoimmunity”.
    [Show full text]